论文部分内容阅读
目的：比较动脉和静脉注射巴曲抗栓酶治疗脑梗死的疗效。方法：用巴曲抗栓酶治疗脑梗死病人９２例，其中动脉组４３例，静脉组４９例，另设对照组（给予右旋糖酐＿４０与复方丹参）４２例。结果：治疗后ｄ２１动脉组和静脉组有效率（均８８％）与对照组（６４％）比较，差异有显著意义（均Ｐ＜０．０５），动脉组和静脉组相比差异无显著意义（Ｐ＞０．０５）。动脉和静脉注射巴曲抗栓酶后不同时间内神经功能改善程度之间差异均无显著性意义（均Ｐ＞０．０５）。巴曲抗栓酶治疗９２例中仅１例出现无症状性脑出血。结论：巴曲抗栓酶治疗脑梗死安全和有效，动脉和静脉用药疗效无差异。
Objective: To compare the curative effect of intravenous injection of batroxobin on cerebral infarction. Methods: 92 cases of cerebral infarction were treated with batroxobin, including 43 cases of arterial group, 49 cases of intravenous group and 42 cases of control group (dextran 40 and compound Salvia miltiorrhiza). Results: There was significant difference between d21 arterial group and intravenous group (both 88%) and control group (64%) after d21 treatment (all P <0.05). There was no significant difference between arterial group and vein group (P> 0.05). There was no significant difference in the improvement of neurological function between arterial and intravenous injection of batroxobin at different time points (all P> 0.05). Asymptomatic intracerebral hemorrhage occurred in only 1 of 92 patients treated with anti-batroxobin. Conclusion: Batroxobin is safe and effective in the treatment of cerebral infarction. There is no difference in the efficacy of arterial and intravenous drugs.